Barclays PLC Increases Position in Omeros Co. (NASDAQ:OMER)

Barclays PLC boosted its position in Omeros Co. (NASDAQ:OMER) by 121.3% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 94,640 shares of the biopharmaceutical company’s stock after acquiring an additional 51,873 shares during the period. Barclays PLC’s holdings in Omeros were worth $376,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. BNP Paribas Financial Markets boosted its holdings in shares of Omeros by 130.6% during the third quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 7,016 shares during the last quarter. MML Investors Services LLC lifted its position in Omeros by 19.2% during the third quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock worth $74,000 after buying an additional 3,000 shares during the period. SPC Financial Inc. acquired a new stake in Omeros in the 3rd quarter worth about $77,000. SG Americas Securities LLC purchased a new stake in Omeros in the 3rd quarter valued at about $80,000. Finally, AQR Capital Management LLC acquired a new position in shares of Omeros during the 2nd quarter valued at about $105,000. 48.79% of the stock is currently owned by institutional investors and hedge funds.

Omeros Stock Up 13.9 %

Omeros stock opened at $11.21 on Friday. The firm has a market capitalization of $649.62 million, a P/E ratio of -4.85 and a beta of 1.97. The firm has a fifty day moving average of $8.32 and a 200-day moving average of $5.62. Omeros Co. has a 52-week low of $2.61 and a 52-week high of $13.60.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Cantor Fitzgerald reissued a “neutral” rating on shares of Omeros in a research report on Thursday, November 14th. D. Boral Capital started coverage on shares of Omeros in a report on Monday, December 23rd. They issued a “buy” rating and a $36.00 price target on the stock. StockNews.com upgraded Omeros from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a research report on Thursday, December 19th. Finally, RODMAN&RENSHAW raised Omeros to a “strong-buy” rating in a research report on Thursday, November 14th. Three analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $22.50.

Omeros Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.